Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Amphastar Pharmaceuticals (AMPH) EBITDA Margin (2016 - 2026)

Amphastar Pharmaceuticals has reported EBITDA Margin over the past 13 years, most recently at 43.06% for Q4 2025.

  • For Q4 2025, EBITDA Margin fell 6726.0% year-over-year to 43.06%; the TTM value through Dec 2025 reached 3.61%, down 2446.0%, while the annual FY2025 figure was 3.61%, 2446.0% down from the prior year.
  • EBITDA Margin for Q4 2025 was 43.06% at Amphastar Pharmaceuticals, down from 13.2% in the prior quarter.
  • Over five years, EBITDA Margin peaked at 40.25% in Q3 2023 and troughed at 43.06% in Q4 2025.
  • A 5-year average of 19.81% and a median of 22.98% in 2021 define the central range for EBITDA Margin.
  • Biggest five-year swings in EBITDA Margin: skyrocketed 2092bps in 2023 and later plummeted -6726bps in 2025.
  • Year by year, EBITDA Margin stood at 20.06% in 2021, then skyrocketed by 40bps to 28.02% in 2022, then grew by 8bps to 30.31% in 2023, then decreased by -20bps to 24.2% in 2024, then crashed by -278bps to 43.06% in 2025.
  • Business Quant data shows EBITDA Margin for AMPH at 43.06% in Q4 2025, 13.2% in Q3 2025, and 24.19% in Q2 2025.